<DOC>
	<DOCNO>NCT00392821</DOCNO>
	<brief_summary>This study do 2 part . The first part determine dose RAD001 use combination sorafenib . The second part use determine dose RAD001 combination sorafenib see effective 2 drug advance kidney cancer . Participants ask keep pill diary .</brief_summary>
	<brief_title>Dosing Effectiveness Study Sorafenib RAD001 Treatment Patients With Advanced Kidney Cancer</brief_title>
	<detailed_description>The drug use trial call target drug target specific activity carry cancer cell make grow spread . Sorafenib approve drug treatment advance kidney cancer . RAD001 experimental drug use research study type cancer . In trial , use RAD001 sorafenib together treatment kidney cancer experimental . In Phase I portion study 13-16 patient treat dose sorafenib different dos RAD001 . The purpose see safe dose RAD001 combine sorafenib treatment kidney cancer . Once dose RAD001 determine , 65 patient treat see effective combination drug kidney cancer . Both drug take mouth . Sorafenib take twice day . RAD001 take mouth weekly . Patients able continue treatment long disease worsen side effect become intolerable .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Clinically document metastatic unresectable locally recurrent clear cell renal carcinoma Previous removal kidney except size tumor le 5 cm extensive liver bone metastasis May prior chemotherapy 1 prior treatment regimen immunotherapy chemotherapy Performance status 01 Measurable disease Adequate liver , renal , bone marrow function Must able give write informed consent Women able become pregnant must negative pregnancy test Must 18 Must able swallow pill Prior treatment sorafenib mTOR inhibitor History acute MI within last 6 month Active brain metastasis patient meningeal metastasis Prior treatment another cancer last 5 year Prior bleed problem ; cough vomit blood Nonhealing wound , ulcer , long bone fracture Chronic use systemic steroid immunosuppressive agent Uncontrolled hypertension Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may . You decide wish participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>